Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19004541.
- Also identified by DOI 10.1016/j.eururo.2008.10.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment options for patients with end-stage renal disease (ESRD) and metastatic renal cell carcinoma (mRCC) are limited. We report the case of a 69-yr-old male who was treated with sorafenib after failure of immunotherapy. The treatment has resulted in remission with stable disease for 13 mo so far. Sorafenib seems to be a safe treatment option for patients with ESRD and mRCC, but further studies are required.
Medical subject headings
- Antineoplastic Agents
- Benzenesulfonates
- Carcinoma, Renal Cell
- Kidney Failure, Chronic
- Kidney Neoplasms
- Pyridines